SynthesisArchives of toxicology2026
Exposure to second-generation flame retardants and risk of metabolic diseases: a systematic review and meta-analysis.
Synthesis in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As replacements for legacy flame retardants, second-generation organophosphorus flame retardants (OPFRs) exhibit high environmental mobility and persistence, resulting in ubiquitous human exposure. The metabolic impacts of OPFR exposure remain controversial despite extensive epidemiological investigation. Comprehensive searches were performed in four databases up to Nov 2025. Following independent selection and quality grading by two reviewers, meta-analysis was conducted using R (version 4.4.3). Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using fixed- or random-effects models, depending on the I² statistic. The robustness of findings was verified via subgroup, sensitivity, and publication bias analyses, while restricted cubic spline regression characterized dose-response relationships. OPFR exposure was significantly associated with an elevated risk of metabolic diseases (OR = 1.11, 95% CI: 1.09–1.14, p < 0.0001). Stronger associations for chlorinated (OR = 1.36, 95% CI: 1.22–1.52) and aryl-OPFRs (OR = 1.39, 95% CI: 1.12–1.72). Significant positive associations in both Chinese (OR = 1.37, 95% CI: 1.19–1.57) and US populations (OR = 1.14, 95% CI: 1.07–1.21). Blood biomarkers yielded higher risk estimates (OR = 1.67, 95% CI: 1.62–2.26) than urine (OR = 1.25, 95% CI: 1.15–1.35). OPFRs were linked to diabetes (OR = 1.39, 95% CI: 1.16–1.68), obesity (OR = 1.35, 95% CI: 1.16–1.57), metabolic liver disease (OR = 1.56, 95% CI: 1.18–2.07), metabolic syndrome (OR = 1.58, 95% CI: 1.32–1.89), and dyslipidemia (OR = 1.18, 95% CI: 1.02–1.37). This study reveals a significant positive association between OPFR exposure and metabolic disease risk, with distinct dose-response patterns identified across various OPFR congeners. This highlights OPFRs as critical environmental risk factors and underscores the public health risks they pose.
Indexed as
Identifiers
41874589What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.